KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Liabilities and Shareholders Equity (2016 - 2025)

NovoCure (NVCR) has disclosed Liabilities and Shareholders Equity for 12 consecutive years, with $804.3 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 35.18% to $804.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.7 billion through Dec 2025, down 2.84% year-over-year, with the annual reading at $804.3 million for FY2025, 35.18% down from the prior year.
  • Liabilities and Shareholders Equity hit $804.3 million in Q4 2025 for NovoCure, down from $1.4 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q3 2025 to a low of $804.3 million in Q4 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2022.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 159.94% in 2021 and later plummeted 35.18% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $1.1 billion in 2021, then rose by 4.58% to $1.2 billion in 2022, then dropped by 3.82% to $1.1 billion in 2023, then grew by 8.26% to $1.2 billion in 2024, then tumbled by 35.18% to $804.3 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for NVCR at $804.3 million in Q4 2025, $1.4 billion in Q3 2025, and $1.2 billion in Q2 2025.